Paper Details

  1. Home
  2. Paper Details

Extended peginterferon plus ribavirin treatment for 72 weeks versus standard peginterferon plus ribavirin treatment for 48 weeks in chronic hepatitis C genotype 1 infected slow-responder adult patients.

Author: Gafter-GviliAnat, GoldvaserHadar, KatzLior H, Tur-KaspaRan

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Overview

The standard treatment for hepatitis C genotype 1 infection is 48 weeks of pegylated interferon and ribavirin, but many patients don't achieve long-term remission. This study explores the potential benefit of extending the treatment duration to improve success rates.
Paper Details　
Original Abstract of the Article :
The standard length of peginterferon plus ribavirin treatment for chronic hepatitis C virus (HCV) genotype 1 infected patients is 48 weeks. However, the number of patients demonstrating a sustained virological response is not high. In order to improve sustained virological response, extending the le...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1002/14651858.CD008516.pub2

データ提供：米国国立医学図書館（NLM）

Extended Peginterferon Plus Ribavirin Treatment for Chronic Hepatitis C

The fight against [chronic hepatitis C] is a formidable challenge, like navigating a treacherous desert landscape. This study, like a beacon of hope in the darkness, explores the potential benefits of extending the duration of treatment with [peginterferon plus ribavirin] for patients with [genotype 1 chronic hepatitis C]. The researchers sought to determine if [extending the treatment period] could improve the chances of achieving a [sustained virological response] in patients who were considered [slow responders] to standard treatment.

Extending Treatment Duration: A Potential Strategy for Improving Response

The study found that [extending the treatment period to 72 weeks] resulted in a [higher rate of sustained virological response] compared to the standard [48-week treatment] for slow-responding patients. This finding is like discovering a hidden oasis in the desert, offering a potential solution for those who have struggled to achieve a sustained response with standard treatment.

Optimizing Treatment Strategies for Hepatitis C

The study highlights the importance of [individualizing treatment strategies] for patients with hepatitis C, taking into account factors such as [genotype] and [response to therapy]. Just as a desert explorer adapts their journey to the unique challenges of the terrain, we must tailor our approach to hepatitis C treatment to optimize the chances of success.

Dr.Camel's Conclusion

This study provides valuable insights into the potential benefits of extending treatment duration with peginterferon plus ribavirin for slow-responding patients with genotype 1 chronic hepatitis C. It's like finding a new path through a treacherous desert, offering hope for a cure. By continuing to explore and refine treatment strategies, we can make significant progress in the fight against hepatitis C.

Date :
  1. Date Completed 2012-10-30
  2. Date Revised 2018-12-21
Further Info :

Pubmed ID

22972122

DOI: Digital Object Identifier

10.1002/14651858.CD008516.pub2

Related Literature

Article Analysis
・Effective treatment of hepatitis c
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.